Drug Profile
Research programme: therapeutic agents - KineMed/Sosei Heptares
Alternative Names: Therapeutic agents research programme - KineMed/Sosei HeptaresLatest Information Update: 13 Dec 2018
Price :
$50
*
At a glance
- Originator KineMed; Sosei
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Connective tissue disorders; Diabetes mellitus; Inflammation; Liver disorders; Metabolic disorders; Neurological disorders; Respiratory tract disorders; Skin disorders
Most Recent Events
- 03 Dec 2018 Heptares Therapeutics has merged with Sosei to form Sosei Heptares
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Connective-tissue-disorders in USA